Chemotherapy vs Targeted Therapy — vs Immunotherapy

There is no single answer, because the side-effect profile depends on the treatment class, your general health, your cancer type and how the treatment is given. Chemotherapy tends to cause side effects throughout the body because it affects all rapidly dividing cells. Targeted therapy has a narrower profile in principle but can cause its own specific reactions depending on which pathway it targets. Immunotherapy's risks are different again — they involve the immune system activating against healthy organs, which can affect the gut, liver, lungs and hormone-producing glands. Your oncologist will explain what to expect from the specific regimen they are recommending.

Not necessarily. Some targeted therapy classes cause hair thinning or loss; others do not. The answer depends on the specific class of treatment being used, not the category as a whole. Ask your oncologist what to expect from the specific regimen they are recommending rather than relying on a general statement about targeted therapy.

No. Immunotherapy is used at different stages depending on the cancer type and the evidence available. For some cancers it is part of the standard approach from early stages; for others it is used in more advanced disease. Being at a particular stage does not make you automatically eligible or ineligible — eligibility still comes back to biomarker testing and the evidence base for your specific cancer type.

Chemotherapy and immunotherapy are administered as day care at CION centres. Targeted therapy, where indicated, is part of the treatment plan CION oncologists coordinate. CION does not provide CAR-T or cell therapy; if that is being considered for your situation, you would be referred to a centre that offers it. Response-assessment scans such as PET-CT are coordinated with partner imaging centres.

The decision draws on your cancer type and stage, what biomarker testing shows about your tumour, your general fitness and the current evidence base for your specific situation. In many cases the answer is not one treatment or another but a sequence or combination. If you want to understand the reasoning behind what is recommended, ask your oncologist which test results drove the decision and what alternatives were weighed.

Ask three things: which treatment is being recommended and why; what testing was done to reach that recommendation and what it showed; and whether a combination approach was considered and why or why not. Write the answers down — these conversations are hard to recall afterwards, and the reasoning behind the recommendation is as important as the recommendation itself.